- Home
- MIST vs BOLD Comparison
MIST vs BOLD Comparison
Compare MIST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIST | BOLD |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 26.9M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | MIST | BOLD |
|---|---|---|
| Price | $2.04 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $8.50 | $4.00 |
| AVG Volume (30 Days) | ★ 9.9M | 131.6K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $1.00 |
| 52 Week High | $3.06 | $3.12 |
Technical Indicators
Market Signals| Indicator | MIST | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 54.65 |
| Support Level | $1.94 | $1.15 |
| Resistance Level | $2.14 | $1.24 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 29.66 | 40.00 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.